Treating intermittent claudication with Tibetan medicine Padma 28: Does it work?

Atherosclerosis

Volumn 189, Issue 1, 2006, Pages 39-46

  Melzer, Jörg ^a   Brignoli, Reto ^b   Diehm, Curt ^c   Reichling, Jürgen ^d   Do, Dai Do ^e   Saller, Reinhard ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Tradyser GmbH   (Switzerland)

^c Klinikum Karlsbad Langensteinbach   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY OF BERN   (Switzerland)

Author keywords

CAM; Maximum walking distance; Meta analysis; Padma 28; Peripheral arterial occlusive disease (PAOD); Phytotherapy; Tibetan herbal drug

Indexed keywords

HERBACEOUS AGENT; PADMA 28; UNCLASSIFIED DRUG;

BLOOD PRESSURE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; INTERMITTENT CLAUDICATION; MEDICAL LITERATURE; PAIN; PERIPHERAL NEUROPATHY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHYTOTHERAPY; PRIORITY JOURNAL; PUBLICATION; REVIEW; SKIN APPENDAGE DISEASE; SKIN MANIFESTATION; SYSTEMATIC REVIEW; TIBETAN MEDICINE; TREADMILL EXERCISE; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT DISEASE; VASCULAR DISEASE;

HUMANS; INTERMITTENT CLAUDICATION; MEDICINE, TIBETAN TRADITIONAL; PHYTOTHERAPY; PLANT EXTRACTS; TREATMENT OUTCOME; WALKING;

EID: 33748973544     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.02.042     Document Type: Review

References (30)

1. Powell J., and Davies A. Peripheral arterial disease. In: Warrell D., Cox T.M., Firth J.D., et al. (Eds). Oxford textbook of medicine. 4th ed. vol. 2 (2004), Oxford University Press, New York 1109-1114
2. Criqui M.H. Peripheral arterial disease-epidemiological aspects. Vasc Med 6 Suppl. 3 (2001) 3-7
3. Lau C.S., Scott N., Shaw J.W., et al. Increased activity of oxygen free radicals during reperfusion in patients with peripheral arterial disease undergoing percutaneous peripheral artery balloon angioplasty. Int Angiol 10 (1991) 244-246
4. Katsube T., Tabata H., Ohta Y., et al. Screening for antioxidant activity in edible plant products: comparison of low-density lipoprotein oxidation assay, DPPH radical scavenging assay, and Folin-Ciocalteu assay. J Agric Food Chem 52 (2004) 2391-2396
5. Chisolm G.M., and Steinberg D. The oxidative modification hypothesis of atherogenesis: an overview. Free Radic Biol Med 28 (2000) 1815-1826
6. Fernandez D.C., Antuna S.S., Martínez E., et al. Ischemia-reperfusion injury in muscular flaps: role of superoxide dismutase and catalase. 6th Internet World Congress for Biomedical Sciences. INABIS (2000). Presentation No. 159 (2000)
7. Novelli G.P., Adembri C., Gandini E., et al. Vitamin E protects human skeletal muscle from damage during surgical ischemia-reperfusion. Am J Surg 173 (1997) 206-209
8. Spark J.I., Chetter I.C., Gallavin L., et al. Reduced total antioxidant capacity predicts ischemia-reperfusion injury after femorodistal bypass. Br J Surg 85 (1998) 221-225
9. Belch J.J., Mackay I.R., Hill A., et al. Oxidative stress is present in atherosclerotic peripheral arterial disease and further increased by diabetes mellitus. Int Angiol 14 (1995) 385-388
10. rGya mtsho, sDS. Gsoba rig pa' bsten bcos smen bla' dgongs rgyen rgyud bzhi' gsal byed be dur snogpo' mallika zhes bya bu bzhugs so-Smed cha [Commentary to the rgyud bzhi, The Blue Beryll-volume II]. Dharamsala: Tibetan Medical & Astro Institute; 1994.
11. Saller R., Kristof O., and Reichling J. Padma 28-ein traditionelles und modernes Phytotherapeutikum [Padma 28-a traditional and modern phytotherapeutic]. Schweizerische Zeitschrift für Ganzheitsmedizin 11 (1999) 28-37
12. ® 28; 2005 [online access: www.kompendium.ch/Monographie.aspx?Id=001ae257-372c-4a41-9cfe-63c3bf8e7c74&lang=de&MonType=fi, accessed 04.05.05].
13. De Backer T.L., Vander Stichele R.H., Warie H.H., et al. Oral vasoactive medication in intermittent claudication: useful or futile?. Eur J Clin Pharmacol 56 (2000) 199-206
14. Mulrow CD, Oxman AD, editors. Cochrane collaboration handbook [updated 9 December 1996]. The Cochrane Collaboration; Issue 1. Oxford: Update Software; 1997 [release date: January 1997].
15. Software RevMan and RevMan manual, 3.0 ed. Monica Fischer, NCC; 1996 [release date: October].
16. Bland M. An introduction to medical statistics. 2nd ed. (1995), Oxford University Press p. 235-8
17. Shao J., and Zhong B. Last observation carry-forward and last observation analysis. Stat Med 22 (2003) 2429-2441
18. Schräder R., Nachbur B., and Mahler F. Die Wirksamkeit des tibetanischen Kräuterpräparates Padma 28 auf die Claudicatio intermittens [Effects of the Tibetan herbal preparation Padma 28 in intermittent claudication]. Schweiz Med Wochenschr 115 (1985) 752-756
19. Samochowiec L., Wojcicki J., Kosmider K., et al. Wirksamkeitsprüfung von Padma 28 bei der Behandlung von Patienten mit chronischen arteriellen Durchblutungsstörungen [Examination of efficacy of Padma 28 in the treatment of patients with chronic arterial circulatory disorder]. Herba Pol 33 (1987) 29-41
20. Sommoggy S, Schleicher P. Therapie der peripheren arteriellen Verschlusskrankheit (PAVK) mit Padma 28. Studie I-Klinische und Immunologische Wirkung von Padma 28 beim Patienten mit PAVK im Stadium II nach Fontaine [Therapy of PAOD with Padma 28. Study I-Clinical and immunological effects of Padma 28 in patients with PAOD stage II according to Fontaine]. Unpublished final report supplied by Department of Vascular Surgery, Technical University Munich & Zytognost GmbH, Munich; June 1990 [Report 26.6].
21. Smulski H.S., and Wojcicki J. Placebo-controlled, double-blind trial to determine the efficacy of the Tibetan plant preparation Padma 28 for intermittent claudication. Altern Ther 1 (1995) 44-49
22. Drabaek H., Mehlsen J., Himmelstrup H., et al. A botanical compound, Padma 28, increases walking distance in stable intermittent claudication. Angiology 44 (1993) 863-867
23. Sallon S., Beer G., Rosenfeld J., et al. The efficacy of Padma 28, a herbal preparation, in the treatment of intermittent claudication: controlled double-blind pilot study with objective assessment of chronic occlusive arterial disease patients. J Vasc Inv 4 (1998) 129-136
24. Samochowiec L., Wojcicki J., Kosmider K., et al. Wirksamkeitsprüfung von Padma 28 bei der Behandlung von Patienten mit chronischen arteriellen Durchblutungsstörungen (Claudicatio intermittens Stadium II nach Fontaine) [Examination of efficacy of Padma 28 in the treatment of patients with chronic arterial circulatory disorder (Claudicatio intermittens stage II acc. to Fontaine)]. Polbiopharm Rep 22 (1987) 3-14
25. Committee for Proprietary Medicinal Products. Note for Guidance on Clinical Investigation of Medicinal Products for the Treatment of Peripheral Arterial Occlusive Disease. CPMP/EWP/714/98, Revision 1; 2002 [online access: www.emea.eu.int/pdfs/human/ewp/071498en.pdf, accessed 04.05.05].
26. Girolami B., Bernardi E., Prins M.H., et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med 159 (1999) 337-345
27. Thompson P.D., Zimet R., Forbes W.P., et al. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 90 (2002) 1314-1319
28. Linde K., ter Riet G., Hondras M., et al. Cochrane complementary medicine field. Systematic reviews of herbal medicines-an annotated bibliography. Forsch Komplementarmed Klass Naturheilkd 10 Suppl. 1 (2003) 17-27
29. Horsch S., and Walther C. Ginkgo biloba special extract EGb 761 in the treatment of peripheral arterial occlusive disease (PAOD)-a review based on randomized, controlled studies. Int J Clin Pharmacol Ther 42 (2004) 63-67
30. Bounameaux H., and Wütschert R. Prise en charge médicale de l'artériopathie des membres inférieurs [Drug treatment strategies for peripheral obliterative arteriopathy]. Drugs 56 Suppl. 3 (1998) 17-23